🔎 Trials Near Me

Inicio › Esclerodermia › Illinois

Ensayos clínicos de Esclerodermia en Illinois

11 estudios sobre Esclerodermia buscan participantes en Illinois.

Ciudades en Illinois

Texto oficial del estudio (inglés)

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

  • University of Illinois Health Outpatient Care Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06655155

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  • Northwestern University, Chicago
  • The University of Chicago Medical Center, Chicago
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07497087

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  • The University of Chicago Medical Center, Chicago
ReclutandoFase 1
Edades de 18 a 74 · Todos los sexos · Actualizado el 10 sept 2026 · NCT07085104

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Chicago
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT05878717

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  • Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
ReclutandoFase 1
Edades de 18 a 70 · Todos los sexos · Actualizado el 28 ago 2026 · NCT06925542

Platform Clinical Study for Conquering Scleroderma

  • The University of Chicago Medical Center (UCMC), Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

  • Northwestern Memorial Hospital, Chicago
  • The University of Chicago Medical Center, Chicago
ReclutandoFase 2/3
Edades de 18 a 75 · Todos los sexos · Actualizado el 17 ago 2026 · NCT06328777

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, Chicago
ReclutandoFase 1/2
Edades de 18 a 75 · Todos los sexos · Actualizado el 7 ago 2026 · NCT06733935

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  • Artiva Investigational Site Willowbrook, Willowbrook
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 jul 2026 · NCT06991114

A Study of AZD0120 in Autoimmune Diseases

  • Research Site, Chicago
ReclutandoFase 1
Edades de 18 a 75 · Todos los sexos · Actualizado el 28 jul 2026 · NCT07295847

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

  • aTyr Investigative Site, Chicago
  • aTyr Investigative Site, Chicago
  • aTyr Investigative Site, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 may 2025 · NCT05892614

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.